Annual ROE
-8.17%
+22.25%+73.14%
31 December 2023
Summary:
CRISPR Therapeutics AG annual return on equity is currently -8.17%, with the most recent change of +22.25% (+73.14%) on 31 December 2023. During the last 3 years, it has risen by +18.63% (+69.51%). CRSP annual ROE is now -108.55% below its all-time high of 95.55%, reached on 31 December 2014.CRSP ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly ROE
-12.15%
+1.70%+12.27%
30 September 2024
Summary:
CRISPR Therapeutics AG quarterly return on equity is currently -12.15%, with the most recent change of +1.70% (+12.27%) on 30 September 2024. Over the past year, it has increased by +7.01% (+36.59%). CRSP quarterly ROE is now -113.05% below its all-time high of 93.07%, reached on 31 March 2016.CRSP Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CRSP ROE Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +73.1% | +36.6% |
| 3 y3 years | +69.5% | -158.6% |
| 5 y5 years | +85.6% | -363.7% |
CRSP ROE High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -143.9% | +73.1% | -158.6% | +60.5% |
| 5 y | 5 years | -143.9% | +85.6% | -145.3% | +60.5% |
| alltime | all time | -108.5% | +85.6% | -113.0% | +96.6% |
CRISPR Therapeutics AG ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | -12.15%(-12.3%) |
| June 2024 | - | -13.85%(+19.8%) |
| Mar 2024 | - | -11.56%(+37.8%) |
| Dec 2023 | -8.17%(-73.1%) | -8.39%(-56.2%) |
| Sept 2023 | - | -19.16%(-11.6%) |
| June 2023 | - | -21.68%(-17.1%) |
| Mar 2023 | - | -26.15%(-15.0%) |
| Dec 2022 | -30.42%(-263.6%) | -30.77%(+1.3%) |
| Sept 2022 | - | -30.39%(+13.7%) |
| June 2022 | - | -26.72%(-298.4%) |
| Mar 2022 | - | 13.47%(-21.6%) |
| Dec 2021 | 18.59%(-169.4%) | 17.19%(-17.1%) |
| Sept 2021 | - | 20.74%(-22.6%) |
| June 2021 | - | 26.81%(-190.3%) |
| Mar 2021 | - | -29.68%(-2.3%) |
| Dec 2020 | -26.80% | -30.37%(+34.3%) |
| Sept 2020 | - | -22.61%(-953.2%) |
| June 2020 | - | 2.65%(-63.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2020 | - | 7.19%(-42.6%) |
| Dec 2019 | 10.04%(-117.6%) | 12.52%(-577.9%) |
| Sept 2019 | - | -2.62%(-95.2%) |
| June 2019 | - | -54.99%(+3.7%) |
| Mar 2019 | - | -53.04%(-0.2%) |
| Dec 2018 | -56.89%(+75.0%) | -53.12%(+21.4%) |
| Sept 2018 | - | -43.76%(+7.4%) |
| June 2018 | - | -40.73%(+15.9%) |
| Mar 2018 | - | -35.13%(+4.1%) |
| Dec 2017 | -32.50%(+42.7%) | -33.75%(+0.1%) |
| Sept 2017 | - | -33.72%(+17.1%) |
| June 2017 | - | -28.79%(-21.9%) |
| Mar 2017 | - | -36.85%(+9.8%) |
| Dec 2016 | -22.78%(-125.7%) | -33.56%(-90.7%) |
| Sept 2016 | - | -361.13%(+333.6%) |
| June 2016 | - | -83.29%(-189.5%) |
| Mar 2016 | - | 93.07%(+45.3%) |
| Dec 2015 | 88.77%(-7.1%) | 64.06% |
| Dec 2014 | 95.55% | - |
FAQ
- What is CRISPR Therapeutics AG annual return on equity?
- What is the all time high annual ROE for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG annual ROE year-on-year change?
- What is CRISPR Therapeutics AG quarterly return on equity?
- What is the all time high quarterly ROE for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG quarterly ROE year-on-year change?
What is CRISPR Therapeutics AG annual return on equity?
The current annual ROE of CRSP is -8.17%
What is the all time high annual ROE for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high annual return on equity is 95.55%
What is CRISPR Therapeutics AG annual ROE year-on-year change?
Over the past year, CRSP annual return on equity has changed by +22.25% (+73.14%)
What is CRISPR Therapeutics AG quarterly return on equity?
The current quarterly ROE of CRSP is -12.15%
What is the all time high quarterly ROE for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high quarterly return on equity is 93.07%
What is CRISPR Therapeutics AG quarterly ROE year-on-year change?
Over the past year, CRSP quarterly return on equity has changed by +7.01% (+36.59%)